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rather than the level of 100,000 used in the paper) of 4%, which
would correspond to 4 deaths over the course of a year
among the 103 thrombocytopaenic patients [10]. Furthermore,
hypoalbuminaemia has also been independently associated with
increased mortality in cirrhotic patients prompting calls for the
adoption of a modiﬁed MELD score incorporating albumin [11].
It seems incontrovertible that cirrhotic patients are at greater risk
of complication from triple therapy, but suggesting that platelet
count (<100,000) and albumin level (<35) should preclude con-
sideration for treatment without describing the natural history
of untreated HCV in a similar cohort appears unbalanced. For
many of these patients, the promise shown in clinical trials of
the next generation of directly acting antivirals, the safety of
which in these cohorts remains also untested may well come
too late.
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Letters to the EditorReply to: ‘‘From the CUPIC study: Great times are not coming (?)’’To the Editor:
Schmidt-Martin and colleagues raised one comment regarding
the main recommendation of our article meaning that patients
with hypoalbuminemia (<35 g/dl) and thrombocytopaenia
(6100,000/mm3) should not be treated with an interferon based
triple therapy due to the high risk to develop severe complications
during the ﬁrst 16 weeks of therapy [1]. As mentioned in the sup-
plementary materials, severe complications were deﬁned as any
of death, grade 3 or 4 infection, hepatic decompensation. The
cause of death, the description of severe infections and hepatic
decompensation were detailed in the results section. A severe
infection (grade 3 or 4) was deﬁned by an infectious episode need-
ing hospitalisation or life-threatening. Among the 6 patients who
died during the ﬁrst weeks of treatment, 3 had hypoalbuminemia
(<35 g/dl) and thrombocytopenia (6100,000/mm3) and the 3
others either hypoalbuminemia or thrombocytopenia.
CUPIC was a cohort in setting of the French early access pro-
gram explaining that all patients received antiviral therapy and
the lack of control group. In ﬁve recent studies (including a
meta-analysis) evaluating the natural history of cirrhotic patients900 Journal of Hepatology 2
Open access under CC BY-NC-ND license.with characteristics comparable to those from the CUPIC cohort,
the annual incidence of deaths and/or liver decompensation var-
ied from 6.2 to 11% on treatment, challenging the indication for
triple therapy in this subgroup of patients [2–6]. In the subgroup
of patients who combined both predictors of severe complica-
tions (albumin <35 g/dl and platelet count 6100,000/mm3), their
occurrence was 44.1% during the ﬁrst 16 weeks. We cannot
exclude that this rate could increase overtime in patients receiv-
ing 48 weeks of therapy. This result strongly suggests that the
risk to develop severe complications is higher in patients with
both predictors treated with triple therapy compared to
untreated cirrhotic patients. We agree that the lack of a control
group does not allow us to distinguish between severe events
caused by treatment from those caused by the cirrhosis itself.
However, based on comparisons with other studies in cirrhotic
patients, the rate of observed severe events was much higher in
this particular group of patient with advanced cirrhosis, low
platelet count and low albumin level. Moreover severe infection
is a relatively rare event in non-treated compensated viral cirrho-
sis. Therefore, it’s likely that the treatment contributed to these014 vol. 60 j 894–901
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access program. Hepatology 2013;58:1108A.
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events. We agree that international treatment guidelines [7–8]
recommend starting triple therapy in HCV genotype 1 patients
with compensated cirrhosis. However, these guidelines were
based on efﬁcacy and safety data reported in cirrhotic patients
included in phase III clinical trials. A crucial point is that low
platelets count and hypoalbuminemia were exclusion criteria
for these studies, meaning that no safety data was available in
such patients at the time of international guidelines. Moreover
it is important to note that patients included in the international
telaprevir early access program patients had severe ﬁbrosis
(n = 741, Metavir F3 or Ishak 3–4) or compensated cirrhosis
(n = 840, Child-Pugh Grade A) and no history of decompensated
liver disease. Additionally, patients must have a platelet count
of at least 90,000/mm3 and albumin >35 g/L [9]. This study does
not allow providing safety data in patients with both predictors
of severe complications. Schmidt-Martin and colleagues suggest
that the poor safety proﬁle in such patients could be explained
by the large number of centers involved in the CUPIC cohort with
variation in the treatment and monitoring protocols. However
there was no impact of the experience of the centre, evaluated
by the number of treated patients (<5 vs. P5 patients) on the
occurrence of severe complications and grade 3/4 anaemia (Hb
<8 g/dl) or blood transfusion.
In summary, we have clearly identiﬁed a subgroup of patients
with a high risk of severe complications raising the question as to
whether these patients, who are the most in need of therapy
should be treated with triple therapy including boceprevir or
telaprevir. In practice, the risk of developing severe complications
or death should be carefully balanced against the likelihood of a
virological response and subsequent improvement of survival
These patients could beneﬁt from prophylaxis (antibiotics) of
treatment complications and should undergo careful monitoring
while on therapy. Alternatively, most of them can wait for all-
oral, IFN-free regimens.
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